Salvestrol cancer therapy
A salvestrol is a natural, dietary phytochemical that can be converted into a cytotoxic metabolite by Cytochrome P450 enzyme CYP1B1 that is overexpressed by cancer cells. The name "salvestrols" was coined by medicinal chemist Gerrard Potter. "Salvestrol" has been trademarked and is used to market dietary supplements and other products. Some salvestrol-based products contain extracts from blackcurrant, blueberry, strawberry, and tangerine peel.
Contents
David icke on salvestrol cancer cure fluor aspartame and vaccines
Initial public reception
On January 1, 2005 The Observer reported that "salvestrols" had been chosen as one of the "20 big ideas" of that year. A 2007 BBC News story reported on a laboratory study that had found salvestrols extracted from tangerine peel show anti-cancer effects. Commenting on this, a spokesperson from Cancer Research UK said, "while this research shows that salvestrols have an effect on cells in the laboratory, there is no evidence that they have a similar effect in patients".
Ineffectiveness of resveratrol
Enthusiasm for resveratrol, the first salvestrol discovered, decreased substantially with additional scientific investigation. A large clinical trial of a resveratrol-based pharmaceutical, SRT-501, was halted when it showed no anti-cancer activity and had significant side effects. Follow-up studies were unable to replicate the purported mechanism of action of resveratrol. In 2012, Dipak K. Das, a researcher at the University of Connecticut whose work focused on the purported health benefits of resveratrol, was found guilty of 145 counts of fabricating or falsifying research data.
Salvesterols have been marketed as dietary supplements promoted for their supposed anti-cancer abilities. According to Andy Lewis, publisher of The Quackometer Blog, "there is no evidence to suggest that these plant-derived chemicals have any positive effect on reducing cancer risk when taken in supplement form or for forming any part of a medical regime for cancer sufferers". In a 2013 Royal Society of Chemistry podcast, Philip Broadwith stated that "despite the lack of reliable data on resveratrol's effects in humans, the compound is still marketed as a dietary health supplement."